Literature DB >> 11738472

Cross linking of polyglutamine domains catalyzed by tissue transglutaminase is greatly favored with pathological-length repeats: does transglutaminase activity play a role in (CAG)(n)/Q(n)-expansion diseases?

Arthur J L Cooper1, Thomas M Jeitner, Vittorio Gentile, John P Blass.   

Abstract

Protein aggregates are a hallmark of Huntington's disease (HD) and other inherited neurodegenerative diseases caused by an elongated (CAG)(n) repeat in the genome and to a corresponding increase in the size of the Q(n) domain in the expressed protein. When the protein associated with HD (huntingtin) contains <35 Q repeats disease does not occur. However, an n>/=40 leads to disease. Some investigators have proposed that aggregates in the nuclei of affected cells are toxic, but other workers have suggested that the aggregates may be neutral or even protective. Whether or not they are toxic, an understanding of the processes whereby the aggregates develop may shed light on the neuropathological processes involved in the (CAG)(n)/Q(n)-expansion disorders. Q(n) domains have a tendency to non-covalently self align as 'polar zippers' rendering them less soluble, but evidence that such polar zippers occur in the aggregates in intact HD brain has so far been limited. The human brain contains at least three Ca(2+)-dependent enzymes (transglutaminases, TGases) that catalyze protein cross-linking reactions, namely TGase 1, TGase 2 (tissue transglutaminase, tTGase) and TGase 3. Q(n) aggregates have been found by several groups to be excellent substrates of tTGase. Moreover, the activity toward the Q(n) domains increases greatly as n is increased to 40 or beyond. tTGase mRNA and total TGase activity are elevated in HD brain. Moreover, some evidence suggests that Ca(2+) homeostasis is disrupted in HD brain. We propose that the combination of increased huntingtin (or huntingtin fragment containing the Q(n) domain) in the nucleus, increased the ability of the Q(n) domains to act as substrate, increased Ca(2+) levels and increased inherent TGase activity all contribute to increased cross-linking of proteins in HD brain. At first the proteasome machinery can recognize and degrade the cross-linked proteins, but over time the proteasome machinery may be overwhelmed and protein aggregates will accumulate.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11738472     DOI: 10.1016/s0197-0186(01)00058-4

Source DB:  PubMed          Journal:  Neurochem Int        ISSN: 0197-0186            Impact factor:   3.921


  13 in total

1.  Therapeutic effects of cystamine in a murine model of Huntington's disease.

Authors:  Alpaslan Dedeoglu; James K Kubilus; Thomas M Jeitner; Samantha A Matson; Misha Bogdanov; Neil W Kowall; Wayne R Matson; Arthur J L Cooper; Rajiv R Ratan; M Flint Beal; Steven M Hersch; Robert J Ferrante
Journal:  J Neurosci       Date:  2002-10-15       Impact factor: 6.167

Review 2.  γ-Glutamylamines and neurodegenerative diseases.

Authors:  Thomas M Jeitner; Kevin Battaile; Arthur J L Cooper
Journal:  Amino Acids       Date:  2012-03-10       Impact factor: 3.520

3.  Analysis of transglutaminase protein substrates by functional proteomics.

Authors:  Margherita Ruoppolo; Stefania Orrù; Alfonsina D'Amato; Simona Francese; Paolo Rovero; Gennaro Marino; Carla Esposito
Journal:  Protein Sci       Date:  2003-06       Impact factor: 6.725

4.  Structural characterization of transglutaminase-catalyzed cross-linking between glyceraldehyde 3-phosphate dehydrogenase and polyglutamine repeats.

Authors:  Margherita Ruoppolo; Stefania Orrù; Simona Francese; Ivana Caputo; Carla Esposito
Journal:  Protein Sci       Date:  2003-01       Impact factor: 6.725

5.  Extracellular matrix modifications at fertilization: regulation of dityrosine crosslinking by transamidation.

Authors:  Julian L Wong; Gary M Wessel
Journal:  Development       Date:  2009-04-29       Impact factor: 6.868

Review 6.  Cellular functions of tissue transglutaminase.

Authors:  Maria V Nurminskaya; Alexey M Belkin
Journal:  Int Rev Cell Mol Biol       Date:  2012       Impact factor: 6.813

7.  Transglutaminase activity is present in highly purified nonsynaptosomal mouse brain and liver mitochondria.

Authors:  Boris F Krasnikov; Soo-Youl Kim; Stephen J McConoughey; Hoon Ryu; Hui Xu; Irina Stavrovskaya; Siiri E Iismaa; Bryony M Mearns; Rajiv R Ratan; John P Blass; Gary E Gibson; Arthur J L Cooper
Journal:  Biochemistry       Date:  2005-05-31       Impact factor: 3.162

8.  Phage display selection of efficient glutamine-donor substrate peptides for transglutaminase 2.

Authors:  Zsolt Keresztessy; Eva Csosz; Jolán Hársfalvi; Krisztián Csomós; Joe Gray; Robert N Lightowlers; Jeremy H Lakey; Zoltán Balajthy; László Fésüs
Journal:  Protein Sci       Date:  2006-11       Impact factor: 6.725

Review 9.  Transglutaminse 2 and EGGL, the protein cross-link formed by transglutaminse 2, as therapeutic targets for disabilities of old age.

Authors:  William Bains
Journal:  Rejuvenation Res       Date:  2013-12       Impact factor: 4.663

Review 10.  Transglutaminases and neurodegeneration.

Authors:  Thomas M Jeitner; John T Pinto; Boris F Krasnikov; Mark Horswill; Arthur J L Cooper
Journal:  J Neurochem       Date:  2009-05       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.